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The CD6 lymphocyte receptor has been involved in the pathophysiology of different 
autoimmune disorders and is now considered a feasible target for their treatment. In vitro 
data show the relevance of CD6 in the stabilization of adhesive contacts between T-cell 
and antigen-presenting cells, and the modulation of T-cell receptor signals. However, the 
in vivo consequences of such a function are yet undisclosed due to the lack of suitable 
genetically modified animal models. Here, the in vitro and in vivo challenge of CD6-deficient 
(CD6−/−) cells with allogeneic cells was used as an approach to explore the role of CD6 in 
immune responses under relative physiological stimulatory conditions. Mixed lymphocyte 
reaction (MLR) assays showed lower proliferative responses of splenocytes from CD6−/− 
mice together with higher induction of regulatory T cells (Treg, CD4+CD25+FoxP3+) with low 
suppressive activity on T and B-cell proliferation. In line with these results, CD6−/− mice 
undergoing a lupus-like disorder induced by chronic graft-versus-host disease (cGvHD) 
showed higher serum titers of anti-double-stranded DNA and nucleosome autoantibod-
ies. This occurred together with reduced splenomegaly, which was associated with lower 
in vivo bromodesoxyuridine incorporation of spleen cells and with increased percentages 
of spleen follicular B cells (B2, CD21+CD23hi) and Treg cells. Interestingly, functional analysis 
of in vivo-generated CD6−/− Treg cells exhibited defective suppressive activity. In conclu-
sion, the data from MLR and cGvHD-induced lupus-like models in CD6−/− mice illustrate 
the relevance of CD6 in T (and B) cell proliferative responses and, even more importantly, 
Treg induction and suppressive function in the in vivo maintenance of peripheral tolerance.
Keywords: cD6 deficiency, Treg cells, chronic graft-versus-host disease, mixed lymphocyte reaction, lupus-like 
mouse model, autoimmunity, peripheral tolerance
Abbreviations: APC, antigen-presenting cells; CD166/ALCAM, activated leukocyte cell adhesion molecule; B2, follicular 
B cells; bm12, B6.C-H-2bm12/KhEg mice; BrdU, bromodesoxiuridine; BSA, bovine seroalbumin; CD6−/−, CD6-deficient; cGvHD, 
chronic graft-versus-host disease; DC, dendritic cell; GC, germinal center B cells; i.p., intraperitoneal; IS, immunological syn-
apse; LAP, latency-associated peptide; LPS, lipopolysaccharide; mAb, monoclonal antibody; MLR, mixed lymphocyte reaction; 
MZ, marginal zone B cells; PWM, Pokeweed mitogen; T1, transitional type 1 B cells; TCR, T-cell receptor; TEM, effector/memory 
T cells; Treg, regulatory T cells; Tconv, conventional CD4+CD25−T cells; TFH, follicular helper T cell; TFR, follicular regulatory T cell.
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inTrODUcTiOn
CD6 was one of the first lymphocyte surface markers identified 
following the advent of monoclonal antibody (mAb) technology 
(1). The fact that CD6 was preferentially expressed by all T cells, 
as well as by a small subset of mature B cells (B1a cells) involved 
in the production of low affinity polyreactive autoantibodies, 
soon led to early though discontinued attempts to treat certain 
autoimmune disorders (e.g., rheumatoid arthritis, psoriasis, and 
multiple sclerosis) using mouse anti-CD6 mAbs (2). The recent 
marketing of a humanized anti-CD6 mAb (itolizumab) (3, 4), 
together with the identification of CD6 gene as a multiple sclerosis 
susceptibility locus (5, 6), has renewed the interest in the study of 
this relatively neglected lymphocyte receptor. Due to the unavail-
ability of genetically modified animal models targeting cd6 gene, 
the rationale for CD6-based therapeutic strategies mostly stems 
from in vitro data. However, when translated into more complex 
in vivo systems, in vitro results have sometimes been misleading. 
This is a key lesson learned from the sister molecule CD5, since 
full characterization of its biological role and development of its 
therapeutic potential could not be realized until CD5-knockout 
mouse models became available (7).
CD6 is a 105–130 kDa transmembrane glycoprotein expressed 
by all mature and developing T  lymphocytes, a subgroup of 
natural killer and B (B1a) cells (1, 8, 9), some hematopoietic cell 
precursors (10) and certain brain cells (11). The main CD6 ligand 
is CD166/ALCAM (activated leukocyte cell adhesion molecule), a 
broadly expressed cell adhesion molecule of the immunoglobulin 
superfamily present on thymic epithelial cells, endothelial cells, 
and antigen-presenting cells (APC) such as dendritic cells, mac-
rophages, and B cells (12). The CD6–CD166/ALCAM interaction 
has recently been structurally solved (13), and it is long known 
to be critical for the stabilization and maturation of the immu-
nological synapse (IS) (14–16), as well as for transmigration of 
T cells to the central nervous system in autoimmune encephalo-
myelitis (17) and arthritis (18) lesions. Previous reports also point 
to a relevant role for CD6 in T-cell development (19) and in the 
regulation of peripheral T-cell activation (14–16, 20, 21).
CD6 has a cytoplasmic tail devoid of intrinsic catalytic 
activity, but includes consensus motifs for Tyr (9) and Thr/Ser 
(22, 23) phosporylation and interaction with different intracel-
lular signaling effectors such as mitogen-activated protein kinases 
(24), SH2 domain-containing leukocyte protein of 76 kDa (SLP-
76) (21, 25) and syntenin (26). This allows CD6 modulating the 
activation responses triggered through the T-cell receptor (TCR)/
CD3 complex to which it is physically associated at the center 
of the IS (14, 15). Whether CD6-dependent signaling events 
modulate positively or negatively T-cell activation in a manner 
similar to that reported to the closely related CD5 lymphocyte 
receptor is a debatable matter (7). Most anti-CD6 mAbs exert co-
mitogenic effects on T cells, suggesting that CD6 may transduce 
costimulatory signals (7). However, such signals may induce 
opposing effects (either activating or inhibitory) depending on the 
experimental system used. This is the case with the UMCD6 mAb, 
which is co-mitogenic in autologous mixed lymphocyte reaction 
(MLR) (27), but inhibits the proliferation of antigen-specific 
and auto-reactive cloned T cells (28). Moreover, attenuation of 
TCR/CD3-mediated early and late T-cell activation responses by 
CD6 overexpression has been reported (20), suggesting that it 
might play a negative modulatory role.
Recent available information from a CD6-deficient (CD6−/−) 
mouse model shows the in  vivo relevance of CD6 in (i) T-cell 
development by increasing the threshold for thymocyte negative 
selection and (ii) the homeostasis of some antigen-experienced 
peripheral T-cell subsets such as effector/memory T cells (TEM) and 
regulatory T cells (Treg), the latter being also dysfunctional (29). 
However, most in vitro studies were conducted under supraphysi-
ological TCR-stimulation conditions—by direct mAb-induced 
cross-linking of the TCR/CD3 complex—and did not take into 
consideration the role assigned to the CD6–CD166/ALCAM 
interaction during adhesive cell-to-cell contacts necessary for 
proper T-cell activation. To further improve our understanding of 
the biological role played by CD6 in the regulation of peripheral 
immune responses, we investigated the in vivo and in vitro con-
sequences of CD6 deficiency during allogeneic stimulation—a 
well-known model of cell contact-dependent antigenic challenge. 
To this end, coisogenic major histocompatibility complex (MHC) 
class II (Ia)-incompatible allogeneic B6.C-H-2bm12/KhEg (bm12) 
splenocytes were used for MLR assays, as well as for induction 
of a lupus-like disorder due to chronic graft-versus-host disease 
(cGvHD) (30). The results presented herein further underscore 
the significant role played by CD6 signaling and/or CD6–CD166/
ALCAM adhesive interactions not only in the induction but also 
the proper regulation of peripheral immune responses.
MaTerials anD MeThODs
Mice
B6.C-H2bm12/KhEg (bm12) mice were obtained from The Jackson 
Laboratory (id. 003625). CD6-deficient (CD6−/−) mice were gen-
erated in C57BL/6N background as reported elsewhere (29). Mice 
were housed under specific pathogen-free conditions. Eight- to 
twelve-week-old CD6−/− and wild-type (CD6+/+) C57BL/6N 
females were used in all experiments following approved pro-
tocols by the University of Barcelona Animal Experimentation 
Ethical Committee.
induction of cgvhD
Following a previously described protocol (30), cGvHD was 
induced in sex and age-matched recipient CD6−/− and CD6+/+ 
mice by intraperitoneal (i.p.) injection of pooled 108 bm12 sple-
nocyte suspensions, previously disaggregated by filtering through 
a cell strainer. Mice were weighted and bled by facial vein weekly. 
Sera samples were stored at −20°C until use.
serum autoantibody Measurements
Serum levels of anti-dsDNA and anti-nucleosoma antibodies 
were measured by ELISA as previously reported (31). Briefly, 
96-well plates (Nunc, Thermo Fisher Scientific, Denmark) were 
coated with nucleosome (3 µg/mL, Arotec) or dsDNA (10 µg/mL, 
Alpha Diagnostic International) in carbonate buffer pH 9.6, 
and incubated overnight (o/n) at 4°C. After washing thrice with 
phosphate-buffered saline plus 0.5% Tween-20 (PBS-T), plates 
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were blocked with 5% bovine seroalbumin in PBS for 1 h at room 
temperature (RT) and further incubated for 2 h at RT with mouse 
sera (1/100 dilution) or mouse antibody anti-dsDNA (HPS22; 
ImmunoTools) used as standard. Plates were then washed thrice 
with PBS-T and, after 1  h incubation at RT with horserad-
ish peroxidase-conjugated anti-mouse IgG (1/2,000, Jackson 
ImmunoResearch) further developed with 3,3′,5,5′-tetrameth-
ylbenzidine substrate solution (BD Biosciences). The colorimetric 
reaction was stopped with 0.5 M H2SO4 (50 µL) and read at 450 
and 620 nm λ on a spectrophotometer (Epoch, Biotek).
cytokine assays
Mouse cytokine (IL-2, IFN-γ) levels in cell culture supernatants 
were measured by ELISA (BD OptEIA sets, BD Biosciences) fol-
lowing manufacturer’s instructions.
Flow cytometry analyses
Surface staining of cells was performed by suspending them in 
blocking solution (10% fetal calf serum in PBS) for 30  min at 
4°C in the presence of the following fluorescent-labeled mAbs: 
anti-B220 (RA3-6B2, eBioscience), anti-CD3 (145-2C11, 
TONBO Bioscience), anti-CD4 (GK1.5, BioLegend), anti-CD8 
(53-6.7, TONBO Bioscience), anti-CD25 (PC61.5, eBioscience), 
anti-CD21 (7G6, eBioscience), anti-CD23 (B3B4, eBioscience) 
and anti-LAP (TW7-16B4, BioLegend), anti-CXCR5 (SPRCL5, 
eBioscience), anti-PD1 (J43, eBioscience), anti-CD138 (281-2, 
BioLegend), anti-CD19 (1D3, TONBO Bioscience), anti-GL-7 
(GL7, eBioscience), anti-IgM (eb121-15-F9, eBioscience), anti-
IgD (11-26c, eBioscience), anti-CD40L (MR1, eBioscience), and 
anti-CD69 (H1.2F3, BioLegend). For intracellular cytokine stain-
ing, cells were exposed to monensin, fixed and permeabilized 
using the BD Cytofix/Cytoperm Plus Kit with BD GolgiStop™ 
(BD Biosciences) following manufacturer’s indications, and then 
stained with specific fluorescent-labeled mAbs: anti-IFN-γ (FITC-
XMG1.2, TONBO Bioscience) and anti-IL-2 (PE-JES6-5H4, BD 
Pharmingen). For FoxP3 staining, the Anti-Mouse/Rat Foxp3 
PE Staining Set (eBioscience) was used following manufacturer’s 
indications. Flow cytometry analyses were performed on a FACS 
Canto II equipped with CellQuest (BD Biosciences) and Flowjo 
8.7 software.
Mlr assays
γ-irradiated (1 cycle, 1,000 rads) stimulator bm12 splenocytes 
(2 × 105 cells/well) were cocultured in U-bottomed 96-well plates 
(Biofil) for 5 days with responder (non-irradiated) total spleno-
cytes or CD4+ T cells (105 cells/well) from CD6−/− or CD6+/+ mice. 
In some cases, Pokeweed mitogen (PWM, Sigma) or anti-CD28 
mAb (TONBO biosciences) were added as costimulatory agents. 
Total splenocyte suspensions were obtained by disaggregation 
through cell strainer and CD4+ T  cells were further isolated 
with Dynabeads Untouched Mouse CD4 T cells kit (Invitrogen) 
following manufacturer’s instructions. As a negative control, 
CD6−/− and CD6+/+ splenocytes were irradiated and used as 
stimulators of total splenocytes or isolated CD4+ T  cells from 
CD6−/− and CD6+/+, respectively. Cells were suspended in RPMI 
1640 with l-glutamine (Lonza), 10% fetal calf serum (BioWest), 
100 U/mL penicillin, 100 µg/mL streptomycin, and 50 µM 2-β 
Mercaptoethanol (Merck), and cultured at 37°C in a humidified 
atmosphere with 5% CO2. Measurement of CD4+ T-cell prolif-
eration was performed by adding 0.5 μCi/well [3H]-thymidine 
(PerkinElmer) 16 h before the end of the stimulation. Cells were 
then harvested in a Wallac cell harvester (Perkin Elmer) and 
incorporated radioactivity was measured in a Wallac Scintillation 
counter (Perkin Elmer) and represented as counts per minute 
(cpm). Flow cytometry assessment of splenocyte proliferation 
was carried out by using the CellTrace™ CFSE cell proliferation 
kit (Molecular Probes, Life Technologies) following manufac-
turer’s instructions.
In Vivo Bromodesoxyuridine  
(BrdU)-incorporation assay
For in  vivo detection of proliferating cells, mice undergoing 
cGvHD were given 1 mg BrdU (BD Pharmingen) i.p. 15 h prior 
to sacrifice at the end of fifth week. Spleen cells were then surface 
stained with different fluorescent-labeled T- and B-cell-specific 
mAbs, and further BrdU-incorporation assessment was done by 
flow cytometry using the FITC BrdU flow kit (BD Pharmingen) 
following manufacturer’s instructions.
regulatory and conventional T-cell 
isolation and In Vitro Treg suppression 
assays
CD4+CD25+ T regulatory cells (Treg) and CD4+CD25− T conven-
tional cells (Tconv) from spleen and lymph node of CD6−/− and 
CD6+/+ mice were sorted by flow cytometry (FACS ARIA III, BD 
Biosciences) following labeling with anti-CD4 (FITC-RM4-5, 
TONBO Bioscience) and anti-CD25 mAb (APC-PC61.5, eBio-
science). The isolated fractions were tested for purity (>  95%) 
and used immediately. The functionality of CD4+CD25+ T cells 
(Treg) was evaluated by measuring their ability to suppress Tconv 
(CD4+CD25−) and B-cell proliferation induced by exposure to 
allogeneic cells and surface IgM cross-linking, respectively. To 
this end, γ-irradiated stimulator bm12 splenocytes (2 × 105 cells/
well) were cocultured for 5 days with CD6+/+ Tconv cells (105 cells/
well) in the presence or absence of different ratios of Treg (2 × 104 
or 104 cells/well) from CD6−/− and CD6+/+ mice. Cell culture 
conditions and cell proliferation assessment by [3H]-thymidine 
cell incorporation was performed as above. Alternatively, 
CFSE-labeled CD6+/+ B sorted cells (see In  Vitro B and T-Cell 
Proliferation Assays) were stimulated for 3 days with goat F(ab’)2 
anti-mouse IgM (10  µg/mL, Jackson ImmunoResearch) in the 
presence or absence of different ratios of Treg (2 × 104 or 104 cells/
well) from CD6−/− and CD6+/+ mice, as previously mentioned. At 
the end of the culture period, cells were analyzed by cytometry 
for assessment of CFSE intensity.
In Vitro Treg induction assay
Sorted Tconv cells (105 cells/well) from CD6−/− and CD6+/+ spleens 
were cultured for 3 days in U-bottomed 96-well plates coated with 
anti-CD3 mAb (145-2C11; 2 µg/mL, TONBO Bioscience) plus sol-
uble anti-CD28 mAb (37.51; 5 µg/mL, TONBO Bioscience) in the 
presence of TGF-β (2 ng/mL, ImmunoTools) and IL-2 (20 ng/mL, 
ImmunoTools). Cells were then stained with anti-CD4 
FigUre 1 | continued
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(FITC-RM4-5), anti-CD25 (APC-PC61.5), and anti-FoxP3 
(PE-3G3, eBioscience) for further flow cytometry analysis of Treg 
(CD4+CD25+FoxP3+) cell induction.
In Vitro B and T-cell Proliferation assays
Spleen B cells from CD6−/− and CD6+/+ were FACS sorted by 
negative selection with anti-CD3 (APC-145-2C11, TONBO 
Bioscience), anti-CD11b (PE-M1770, eBioscience), and anti-
CD11c (PerCPCy5.5-N418, TONBO Bioscience) mAbs. Spleen 
Tconv (CD4+CD25−) cells were sorted as above described. 
The isolated fractions were tested for purity (>95%) and 
CSFE-labeled as above. Purified B  cells (105 cells/well) were 
then cultured for 3  days in the presence of goat F(ab’)2 anti-
mouse IgM fragment (10  µg/mL, Jackson ImmunoResearch) 
or lipopolysaccharide (LPS, 20 µg/mL, Sigma) with or without 
IL-4 (10  ng/mL, ImmunoTools) or anti-CD40 mAb (1C10, 
Biolegend; 5 µg/mL). CSFE-labeled purified CD4+ T cells were 
also cultured for 3 days in U-bottomed 96-well plates coated 
with anti-CD3 mAb (145-2C11; 2  µg/mL). At the end of the 
culture period, cells were analyzed by cytometry for assessment 
of CFSE intensity.
rna extraction and Quantitative real-time 
rT-Pcr
Total RNA extraction from cell cultures was performed as previ-
ously described (32, 33). Mouse IL-2, IL-17, CD40L, IFN-γ, and 
β-actin expression was measured by quantitative real-time PCR 
using SYBR Green Real-Time PCR Master Mix kit (ThermoFisher 
Scientific) and the following specific primers: IL-2: Fw 5′-TGT 
TGA TGG ACC TAC AGG AG, Rv 5′-GTG TTG TCA GCC 
CTT TAG; IL-17: Fw 5′-CTG TGT CTC TGA TGC TGT TG, 
Rv 5′-TAT CAG GGT CTT CAT TGC GG; CD40L: Fw 5′-ACT 
GTG AGG AGA TGA GAA GC, Rv 5′-ACT GTA GAA CGG 
ATG CTG; IFN-γ: Fw 5′-TCA AGT GGC ATA GAT GTG GAA 
G, Rv 5′-TGG CTC TGC GGA TTT TCA TG; and β-actin: Fw 
5′-CGC GTC CAC CCG CCA C, Rv 5′-CCT GCT GCC TAG 
GCG. The level of expression of β-actin was used to normalize 
gene expression.
statistical analyses
Data were expressed as mean ±  SD. Statistical analyses were 
performed by parametric t-tests for paired data using GraphPad 
Prism (GraphPad Software). *p values ≤ 0.05, **p values ≤ 0.01, 
and ***p values ≤ 0.001 were considered statistically significant.
resUlTs
cD6−/− T cells exhibit low In Vitro 
Proliferative responses to allogeneic 
stimulation
Available in vitro evidence indicates that adhesive CD6 signaling 
and/or adhesive CD6–CD166/ALCAM interaction is required 
for optimal T-cell activation and proliferation (14, 16). To 
further investigate in vitro proliferative responses of peripheral 
T cells from CD6−/− mice under cell-to-cell contact-dependent 
antigenic stimulation, MLR assays were performed. To this end, 
irradiated bm12 (bm12#) splenocytes—which differ from those 
of C57BL/6N by three amino acids in the β-chain of their I-A 
molecules—were cocultured for 5  days at 2:1 ratio with non-
irradiated CFSE-labeled splenocytes from CD6−/− or CD6+/+ 
mice, respectively. As illustrated in Figure 1A, responder CD6−/− 
splenocytes showed statistically significant lower proliferative 
responses than CD6+/+ ones, a fact that did not happen in the 
FigUre 1 | continued  
In vitro activation and proliferative responses of spleen cD6−/− cells 
to allogeneic mixed lymphocyte reaction (Mlr) stimulation. 
(a) Responder CFSE-stained total splenocytes from CD6−/− (solid bars) or 
CD6+/+ (empty bars) mice were cocultured for 5 days at a 2:1 ratio with 
irradiated total bm12 splenocytes (bm12#) as stimulators. Percentage 
(mean ± SD) of proliferating B cells (CFSElow) following MLR-induction alone 
or in the presence of Pokeweed mitogen (PWM) is shown. Data shown are 
triplicate samples from one representative experiment of three performed.  
(B) Spleen CD4+ T cells isolated by negative selection from CD6−/− (solid 
bars) or CD6+/+ (empty bars) mice were cocultured for 5 days with irradiated 
bm12 splenocytes (bm12#) in the presence or absence of anti-CD28 
monoclonal antibody (mAb) (α-CD28, 1 µg/mL). The bar chart shows the 
[3H]-thymidine incorporation (in cpm) of triplicate samples from one 
representative experiment of four performed. (c) Same sorted CD4+ T cells 
from (B) were stimulated for 24 h and analyzed for CD40L, CD69, and CD25 
surface expression in CD4+ gated T cells by flow cytometry. A representative 
experiment of three performed is shown. (D) Bart charts representing the 
IL-2 (left-hand side) and IFN-γ (right-hand side) levels (pg/mL) over time from 
supernatants of same cocultures as in (B). (e) Percentage (mean ± SD) of 
intracellular IL-2-positive cells among CD4+ spleen T cells from day 5 of 
same cocultures as in (B). (F) IL-2 levels (pg/mL) over time from 
supernatants of same cocultures as in (B) in the presence of exogenously 
added blocking anti-CD25 mAb (30 µg/mL). n.s., not significant; *p < 0.05; 
**p < 0.01; ***p < 0.001 (Student’s t-test).
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presence of costimulation with PWM—a monocyte-dependent 
T (and B) cell activator (34). Given that the MLR system here used 
is driven by MHC class II allorecognition, purified CD4+ spleen 
T cells from CD6−/− and CD6+/+ mice were used as responders 
to irradiated bm12 stimulator cells at 2:1 ratio. Similar to results 
obtained with CFSE-labeled total splenocytes, CD4+ T cells from 
CD6−/− mice showed statistically significant lower [3H]-thymidine 
incorporation than those from CD6+/+ (Figure 1B). Worthy of 
note, these proliferative differences also disappeared when an 
anti-CD28 mAb was added as a costimulatory agent. Moreover, 
no significant differences regarding apoptotic cell numbers were 
detected between CD6−/− and CD6+/+ responder cells in MLR 
assays (data not shown).
The fact that CD6-mediated interactions are relevant to IS 
formation and maturation (14–16) would suggest that deficient 
TCR signal strength could account for the lower T-cell prolif-
erative response to allogeneic stimulation observed in CD6−/− 
mice. Consequently, the induction of early surface markers 
of T-cell activation events at mRNA and protein levels was 
analyzed at 7 and 24 h, respectively, following allogeneic stimu-
lation of CD4+ T cells from CD6+/+ and CD6−/− with irradiated 
allogeneic (bm12#) splenocytes. As shown in Figure 1C, CD40L 
and CD69 surface expression was also lower in CD6−/− T cells 
compared to CD6+/+ ones, reaching statistically significant 
values only for the former (Figure 1D). On the contrary, CD25 
surface expression was found significantly increased in CD6−/− 
T cells. Interestingly, no significant differences were observed 
for any of the early activation events analyzed when CD6−/− and 
CD6+/+ T cells were challenged via CD3 cross-linking, used as 
a positive stimulation control. Taken together, the small dif-
ferences observed in early T-cell activation markers stemming 
from our allogeneic model do not allow unequivocally support-
ing attenuated signal strength as a likely underlying cause of 
lower T-cell proliferation observed in CD6−/− mice post-MLR 
stimulation.
Monitoring of MLR culture supernatants from CD6−/−-
deficient CD4+ T  cells showed significantly lower IL-2 and 
IFN-γ cytokine levels at all time points analyzed when com-
pared with their CD6+/+ counterparts (Figure 1D). Intracellular 
cytokine staining of MLR cocultures revealed that CD4+ T cells 
from CD6−/− spleens did not present lower, but similar percent-
age of IL-2-positive cells compared to those from CD6+/+ mice 
(Figure  1E). Since these data favored the idea of increased 
cytokine consumption rather than defective cytokine produc-
tion as responsible for low cytokine levels in MLR culture 
supernatants, same assays were performed in the presence of 
a blocking anti-CD25 (IL-2 receptor α chain, IL-2Rα) mAb. 
As shown in Figure  1F, addition of the anti-CD25 mAb to 
the MLR culture abrogated the abovementioned differences in 
IL-2 supernatant levels between CD6−/− and CD6+/+ alloreac-
tive CD4+ T  cells, thus pointing to an accelerated cytokine 
consumption.
Preserved Proliferative responses of 
cD6−/− T cells to Direct antigen-specific 
receptor cross-linking
In light of results depicted in Figures  1C,D, it was further 
assessed whether cell-intrinsic defects could account for the 
lower in  vitro proliferation found in CD6−/− mice following 
allogeneic stimulation. To this end, sorted CD4+ T  cells were 
CFSE-labeled and their proliferative response measured by 
flow cytometry upon 3-day stimulation via mAb-induced CD3 
cross-linking. As shown in Figure 2A, no statistically significant 
differences were observed between CD6−/− and CD6+/+ CD4+ 
T  cells regarding their CD3-mediated proliferative responses. 
Moreover, no significant differences were also observed when 
mRNA expression levels for IL-2 and IFN-γ (Figure 1C), as well 
as IL-17, CD40L, and IL-10 (Figure 2B) were assessed from the 
same in vitro CD3-stimulated CD4+ T cells. Taken together, these 
results argue against significant T-cell-intrinsic defects associated 
with CD6 deficiency.
cD6−/− cD4+ T cells Differentiate More 
efficiently into FoxP3+ cells Following 
allogeneic stimulation
The MLR results on low proliferative T-cell responses in asso-
ciation with high IL-2 consumption led us to explore the in vitro 
induction of Treg cells—a functionally relevant T cell subset known 
to consume a large fraction of the IL-2 produced by activated 
CD4+ T cells (35). To this end, the frequency of CD25+FoxP3+ 
cells was assessed by flow cytometry at different time points fol-
lowing coculture of purified CD4+ T-cells from CD6−/− or CD6+/+ 
mice with allogeneic irradiated bm12 splenocytes. As illustrated 
by Figure  3A, statistically significant increased percentages of 
CD25+FoxP3+ cells were observed at all time points analyzed in 
MLR cultures using CD6−/− cells as responders, compared to their 
CD6+/+ counterparts. These differences were maintained even in 
the presence of exogenously added IL-2 but were abrogated in the 
presence of blocking anti-CD25 mAb or agonist anti-CD28 mAb 
FigUre 3 | In vitro generation and functional analysis of spleen 
regulatory T cells from cD6−/− mice. (a) Purified CD4+ T cells (105 cells/
well) from CD6−/− (solid bars) or CD6+/+ (empty bars) spleens were cocultured 
with irradiated bm12 splenocytes (bm12#) at a 2:1 ratio for different periods 
of time for further flow cytometry analysis. Data are shown as percentage 
(mean ± SD) of CD25+FoxP3+ cells on gated CD4+ cells from duplicates of 
one representative experiment of four performed. Control means the results 
of coculturing responder CD6−/− or CD6+/+ cells with irradiated splenocytes 
from the same responder. (B) Same 72 h cocultures as in (a) in the absence 
(bm12#) or the presence of exogenously added IL-2 (+IL-2; 150 pg/mL), 
blocking anti-CD25 monoclonal antibody (mAb) (+αIL-2, 30 µg/mL) or 
agonistic anti-CD28 mAb (+ αCD28; 5 µg/mL). (c) Sorted (105 cells/well) 
conventional CD4+CD25− T cells (Tconv) from CD6−/− (solid bars) or CD6+/+ 
(empty bars) spleens were cultured for 3 days with plastic-bound anti-CD3 
mAb (2 µg/mL) plus soluble anti-CD28 mAb (5 µg/mL) in the presence or 
absence of TGF-β (2 ng/mL) alone or plus IL-2 (20 ng/mL). (D) Flow 
cytometry analysis of latency-associated peptide (LAP) surface expression on 
CD4+ gated CD25+FoxP3+ T cells generated at 72 h as in (a) (left) or as in 
(c) (right). Shown is a representative experiment of four performed. n.s., not 
significant (Student’s t-test).
FigUre 2 | In vitro activation and proliferative responses of spleen 
cD4+ T cells from cD6−/− and cD6+/+ mice to cD3 cross-linking. 
 (a) Sorted spleen CD4+ T cells from untreated CD6−/− and CD6+/+ mice were 
CFSE-labeled and cultured for 3 days either alone or plastic-bound anti-CD3 
monoclonal antibody (1 µg/mL) for further flow cytometry analysis. The 
histogram shows the CFSE fluorescence intensity from a representative 
experiment of four performed, at different time points. (B) CD4+ T cells 
stimulated as in (a) for 7 h were analyzed for mRNA expression levels of the 
indicated genes by real-time PCR. The bar charts represent quintuplicate 
mRNA values from six pooled mice, where ΔCt indicates the difference in the 
threshold cycle between GADPH and target genes. n.s., not significant 
(Student’s t-test).
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(Figure 3B). Interestingly, no statistically significant differences 
were not observed when assessed the frequency of CD25+FoxP3+ 
cells following stimulation of purified CD4+ T-cells under con-
ventional Treg induction conditions—that is, anti-CD3 plus anti-
CD28 mAbs in the presence of Treg-inducing cytokines TGF-β 
and IL-2 (Figure 3C). This indicates both that (i) CD6 expression 
is relevant to proper Treg induction during cell contact-dependent 
allogeneic stimulation and (ii) contact-independent and supra-
physiological conventional conditions for in  vitro induction of 
Treg abrogates the differences found between CD6−/− and CD6+/+ 
T cells.
Moreover, surface expression of latency-associated peptide 
(LAP)—the N-terminal pro-peptide of the TGF-β precursor, 
which is considered to confer regulatory function to T cells and 
to be a selective marker of activated Treg (36, 37)—was found 
to be lower on MLR-induced CD4+CD25+FoxP3+ T  cells from 
CD6−/− mice compared to those of CD6+/+ (Figure 3D, left). No 
differences regarding LAP expression were, however, observed 
on CD4+CD25+FoxP3+ T cells from CD6−/− mice induced under 
FigUre 6 | anti-dsDna and anti-nucleosoma autoantibody titers in 
aged cD6−/− and cD6+/+ mice. Serum levels of autoantibodies against 
nucleosome (left-hand side) and dsDNA (right-hand side) from untreated 
CD6−/− (n = 5, filled circles) and CD6+/+ (n = 5, empty circles) mice at 3, 6, 9, 
and 12 months of age were determined by ELISA. Data are expressed as 
mean ± SD of duplicates from a representative experiment of two performed. 
*p < 0.05; **p < 0.01 (Student’s t-test).
FigUre 5 | Phenotypical characterization of cD6−/− and cD6+/+ mice 
following chronic graft-versus-host disease (cgvhD)-induced 
lupus-like disease. (a) ELISA determination of serum levels of 
autoantibodies against nucleosome (left) and dsDNA (right) at different weeks 
post-induction of cGvHD in CD6−/− (n = 6; solid circles) and CD6+/+ (n = 6; 
empty circles) mice. Results are from one representative experiment of three 
performed and are expressed as mean ± SD of OD at 450 nm (anti-
nucleosome) or concentration in microgram per milliliter (anti-dsDNA).  
(B) Percentage of weekly body weight variation (mean ± SD) with regard to 
initial weight from the same mice groups as in (a). (c) Left, total spleen cell 
numbers pre and post (week 5) GvHD induction in the same mice groups as 
in (A). (c) Right, spleen weight (mg) at week 5 post cGvHD from same mice 
groups as in A. The results are the mean ± SD from one representative 
experiment of three performed. n.s., not significant; *p < 0.05; **p < 0.01; 
***p < 0.001 (Student’s t-test).
FigUre 4 | relative mrna expression levels of in vivo isolated 
cD4+cD25+ cells from cD6−/− and cD6+/+ mouse spleens following 
direct T-cell receptor complex cross-linking. Sorted CD4+CD25+ T cells 
[regulatory T cells (Treg)] from CD6−/− (n = 5, solid bars) and CD6+/+ (empty 
bars) were stimulated in anti-CD3 (1 µg/mL) coated plates. Relative mRNA 
expression for the indicated genes was measured after 7 h of stimulation by 
real-time PCR. n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001 (Student’s t-test).
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the abovementioned conventional conditions (anti-CD3 + CD28 
plus TGF-β/IL-2) (Figure 3D, right). These results are indicative 
of a relative defective activation and/or function of CD6−/− Treg 
cells under contact-dependent (MLR) but not contact-independ-
ent (anti-CD3 + CD28 plus TGF-β/IL-2) inductive conditions. 
Accordingly, direct TCR/CD3 cross-linking of CD4+CD25+ 
cells from CD6−/− and CD6+/+ mice did not reveal statistically 
significant differences regarding relative mRNA expression levels 
of different lymphocyte activation-related genes (IL-2, IL-17, 
CD40L, and IFN-γ) (Figure 4).
cD6−/− Mice show exacerbated cgvhD-
induced lupus-like Disease
To further address the in  vivo significance of the abovemen-
tioned MLR data (low lymphoproliferative responses and 
higher induction of putatively dysfunctional Treg cells), a 
cGvHD-mediated autoimmune syndrome resembling systemic 
lupus erythematosus (30) was induced by challenging mice 
with coisogenic allogeneic cells. To this end, recipient CD6−/− 
and CD6+/+ mice were injected (i.p.) with a single dose (108 
cells) of donor age/sex-matched allogeneic bm12 splenocytes 
(38). Weekly monitoring of serum autoantibody production 
revealed statistically significant increased levels of anti-dsDNA 
and anti-nucleosome in CD6−/− mice compared to their 
CD6+/+ counterparts from the second week post-cell transfer 
(Figure 5A). This phenomenon was not only observed follow-
ing cGvHD induction but also spontaneously with aging. As 
illustrated by Figure 6, low but still significant higher levels of 
autoantibodies were detected in aged CD6−/− mice from their 
ninth month of life.
Moreover, body weight gain associated with serositis 
(e.g., ascites) and lymphoid organomegaly phenomena com-
mon in the cGvHD-induced model (30, 38) were also statisti-
cally increased in CD6−/− mice (Figure  5B). The assessment 
of splenomegaly at the end of the follow-up period (week 5) 
showed, however, statistically significant lower total spleen cell 
numbers (Figure 5C, left) and spleen weight (Figure 5C, right) 
in CD6−/− mice compared with their CD6+/+ counterparts. No 
differences regarding total spleen cell numbers (Figure 5C, left) 
were detected between CD6+/+ and CD6−/− mice before induction 
of cGvHD-mediated lupus-like disease indicating that variances 
observed following bm12 cell injection could directly be related 
to differences in CD6 expression.
FigUre 7 | lymphocyte subset analysis of spleens from cD6−/− and cD6+/+ mice undergoing chronic graft-versus-host disease (cgvhD)-induced 
lupus-like disease. (a) Flow cytometry contour plots of B220+ cells and percentage (mean ± SD) of B220+, CD4+, and CD8+ cells from total spleens harvested at 
week 5 post cGvHD induction in CD6−/− (n = 6; solid bars) and CD6+/+ (n = 6; empty bars) mice. (B) Flow cytometry contour plots and percentages (mean ± SD) of 
spleen B220+ cells with marginal zone B cells (MZ, CD21+CD23low), follicular (B2, CD21+CD23+), and transitional type 1 (T1, CD21−CD23−) phenotypes from the 
same groups of mice as in (a). (c) Percentages (mean ± SD) of memory (CD19+CD138−IgD−IgM−), plasma (CD19− CD138+), and germinal zone B-cells 
(CD19+GL-7+) from the same groups of mice as in (a). (D) Percentages (mean ± SD) of follicular helper (TFH; CD4−CXCR5+PD1+) and follicular regulatory T cells (Treg) 
(TFR; CD4−CXCR5+PD1+ FoxP3+) from the same groups of mice as in (a). (e) Left, Percentage (mean ± SD) of CD4+ spleen T cells with regulatory (CD25+FoxP3+) 
and activated (CD25+FoxP3−) phenotypes from the same groups of mice as in (a). (e) Right, Increment in the percentage of spleen Treg (CD4+CD25+FoxP3+) cells at 
week 5 postinduction of cGvHD in the same groups of mice as in (a). Results are expressed as the ratio (mean ± SD) resulting from dividing the percentage of Treg 
at week 5 by that at week 0. (F) Flow cytometry contour plots and percentage (mean ± SD) of BrdU+ cells from total, B220+ and CD4+ splenocytes at week 5 from 
the same groups of mice as in (a). (g) Percentage (mean ± SD) of total spleen cells with late-stage apoptotic phenotype (Annexin V+ 7-AAD+) from the same groups 
of mice as in (a). In all cases, data shown are from one representative experiment of three performed. n.s., not significant; BrdU, bromodesoxyuridine; **p < 0.01; 
***p < 0.001 (Student’s t-test).
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cD6−/− Mice Undergoing cgvhD-induced 
lupus-like Disease show increased 
Frequency of Follicular B cells and 
Dysfunctional Treg cells
The flow cytometry analysis of major spleen lymphocyte sub-
populations from week 5 post-GvHD induction revealed statisti-
cally significant increased percentages of B220+ (B) cells among 
CD6−/− mice compared to CD6+/+ mice, while no significant 
differences were observed regarding the percentage of CD4+ and 
CD8+ T  cells (Figure  7A). A more detailed analysis of B220+ 
spleen cell subsets revealed a significantly increased percentage of 
follicular cells (B2; CD21+CD23hi) concomitant with a significant 
reduction in that of transitional type 1 (T1; CD21−CD23−) B cells 
(Figure 7B). No significant differences were observed in the per-
centage of marginal zone B cells (MZ; CD21+CD23low), memory 
(CD138−IgD−IgM−), plasma (CD19− CD138+) and germinal 
center (CD19+GL-7+) B cells (Figures 7B,C).
The subanalysis of spleen CD4+ T  cells revealed a signifi-
cantly increased percentage of cells with regulatory phenotype 
FigUre 8 | In vitro proliferative responses of B220+ cells from 
cD6−/− and cD6+/+ mice to igM cross-linking and lipopolysaccharide 
(lPs) stimulation. (a) Negatively selected spleen B cells from CD6−/− and 
CD6+/+ mice were CFSE-labeled and cultured for 3 days either unstimulated 
(w/o stimulus) or stimulated with F(ab′)2 anti-IgM (αIgM; 10 µg/mL) alone or in 
the presence of anti-CD40 (αCD40; 5 µg/mL) or IL-4 (10 ng/mL). (B) Same 
cells as in (a) were stimulated for 3 days with LPS (20 µg/mL) alone or plus 
IL-4 (30 ng/mL). Histograms show the CFSE fluorescence intensity of cells 
from a representative experiment of two performed.
9
Consuegra-Fernández et al. Allogeneic Responses and CD6-Deficiency
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 594
(CD25+FoxP3+) concomitant with a non-significant reduction 
of cells with activated/effector phenotype (CD25+FoxP3−) 
(Figure  7D). Although higher basal percentages of spleen 
CD4+CD25+FoxP3+ cells can be detected in CD6−/− versus 
CD6+/+ mice pre-cGvHD induction (29), the increment at week 
5 post cGvHD was higher for CD6−/− mice compared to that 
of CD6+/+ ones (Figure  7D, right). No statistically significant 
differences were observed regarding follicular helper (TFH, 
CD4−CXCR5+PD1+) and follicular regulatory (TFR, CD4−CXCR5
+PD1+FoxP3+) T-cell subsets (Figure 7E).
Further assessment of the underlying causes of lower spleno-
megaly found in CD6−/− mice undergoing cGvHD was carried out 
by analyzing in vivo the levels of both proliferating and apoptotic 
spleen cells. With regard to the former, recipient CD6+/+ and 
CD6−/− mice at week 5 post cGvHD induction were administered 
(i.p.) BrdU 15  h prior to sacrifice for further flow cytometry 
analysis. These in  vivo BrdU-incorporation assays revealed a 
statistically significant lower percentage of BrdU+ spleen cells 
among CD6−/− mice compared to CD6+/+ (Figure 7F). A more 
detailed analysis showed that both B220+ and CD4+ T cells from 
CD6−/− mice incorporated less BrdU than those from CD6+/+ ones, 
though differences only reached statistical significance for B220+ 
cells. Investigation of spleen apoptotic cell levels by Annexin V 
and 7-AAD staining showed no statistically significant differences 
between CD6−/− and CD6+/+ mice (Figure 7G), supporting lower 
proliferation as the main putative cause of reduced splenomegaly.
Though spleen B cells are mostly CD6 negative, in vitro B-cell 
proliferation assays were also performed in order to exclude 
B-cell-intrinsic defects as responsible for low in vivo proliferation 
found in CD6−/− mice following cGvHD-induced lupus-like. To 
this end, sorted B220+ splenocytes from CD6−/− and CD6+/+ mice 
were CFSE-labeled and then stimulated with either F(ab’)2 anti-
IgM or LPS in the presence or absence of anti-CD40 mAb or IL-4 
costimulation. As shown in Figures 8A,B, similar B-cell prolif-
erative responses were observed under all stimulatory conditions 
for CD6−/− and CD6+/+ mice, thus arguing against the existence of 
B-cell-intrinsic defects associated with CD6 deficiency.
Defective suppressive Function of spleen 
cD4+cD25+ T cells from cD6−/− Mice
The fact that higher Treg induction observed after in  vivo (and 
in vitro) allogeneic stimulation did not prevent the presence of 
higher levels of circulating autoantibodies led to further assess 
the suppressive properties of CD6−/− Treg cells. To this end, 
sorted spleen CD4+CD25+ T  cells (Treg) from either CD6−/− or 
CD6+/+ mice at week 5 post cGvHD induction were subjected 
to flow cytometry analysis of intracellular and surface FoxP3 
(Figure  9A) and LAP expression (Figure  9C), respectively. As 
shown in Figure  9B, sorted CD4+CD25+ T  cells from CD6−/− 
mice presented higher percentage of FoxP3 expression compared 
to CD6+/+ mice. Interestingly, lower surface expression levels of 
LAP were also observed for CD6−/− mice (Figure 9C), which is 
suggestive of lower suppressive activity.
The same sorted CD4+CD25+ T  cells were further tested in 
Treg suppression assays. Accordingly, such cells were added at 
different cell ratios to cocultures of Tconv (CD4+CD25−) T  cells 
from CD6+/+ mice used as responders, and irradiated total bm12 
splenocytes used as stimulators. Proliferative responses meas-
ured by [3H]-thymidine incorporation at day 5 poststimulation 
showed a statistically significant lower suppressive activity for Treg 
cells from CD6−/− mice compared to their CD6+/+ counterparts 
(Figure  9D). Similar results were obtained when testing the 
suppressive activity of spleen Treg from untreated (pre-cGvHD 
induction) CD6−/− and CD6+/+ mice (data not shown), thus 
indicating that CD6 deficiency imposes a Treg dysfunction which 
is not overcome post cGvHD induction.
The suppressive activity of Treg cells from untreated (pre-
cGvHD induction) CD6−/− and CD6+/+ mice on B cells was also 
assessed by their coculture with CFSE-labeled sorted B220+ 
CD6+/+ splenocytes (Figure 9E, left) stimulated with F(ab′)2 anti-
IgM. As shown in Figure 9E (right), significant lower suppressive 
activity was observed at different cell ratios for Treg from CD6−/− 
mice compared to their CD6+/+ counterparts. This indicates the 
existence of a general functional defect of Treg in the absence of 
CD6 expression.
DiscUssiOn
A balance between generation and function of effector/memory 
and Treg is decisive for eliciting protective immune responses 
and keeping autoimmunity at bay (39). This report shows that 
CD6—a component of the TCR complex signaling machinery—
influences such equilibrium by shaping the number and function 
of peripheral Treg.
The spontaneous generation of peripheral but not thymus-
derived CD4+CD25+FoxP3+ cells in CD6−/− mice has been 
described (29). Our in vitro (MLR assays) and in vivo (cGvHD-
induced lupus-like model) results provide new clues as to why 
this happens. The experimental system described herein involves 
FigUre 9 | Functional assessment of the suppressive activity of in vivo isolated cD4+ cD25+ spleen T cells from cD6−/− and cD6+/+ mice. (a) Density 
plot histogram showing the fluorescence intensity of conventional CD4+CD25− (Tconv) and regulatory CD4+CD25+ [regulatory T cells (Treg)] spleen T cells from CD6+/+ 
mice subjected to further FACS sorting. (B) Contour plot and percentages (mean ± SD) of FoxP3 expression in sorted CD4+CD25+ T cells 5 weeks after chronic 
graft-versus-host disease induction. (c) Flow cytometry analysis and percentages (mean ± SD) of latency-associated peptide (LAP) surface expression on CD4+ 
gated CD25+FoxP3+ T cells from spleens of untreated CD6−/− and CD6+/+ mice. (D) Sorted Tconv cells from untreated CD6+/+ mice were cocultured at a 2:1 ratio with 
irradiated bm12 splenocytes alone or in the presence of sorted Treg from CD6−/− (solid circles) or CD6+/+ (empty circles) mice at week 5 post GvHD induction, added 
at the indicated Tconv:Treg ratios. Shown is the [3H]-thymidine incorporation (in cpm) after 5 days of coculture. (e) Left, density plot histogram showing the sorting 
strategy to isolate B220+ cells from CD6+/+ mice (e) Right. Sorted spleen B220+ cells from wild-type (CD6+/+) mice were CFSE-labeled and cultured for 3 days in the 
presence of F(ab’)2 anti-IgM fragments (10 µg/mL) alone or plus sorted CD4+CD25hi (Treg) splenocytes from CD6−/− (solid circles) or CD6+/+ (empty circles) mice, at the 
indicated B:Treg ratios. The line chart show the percentage (mean ± SD) CFSElow cells from a representative experiment of two performed. Data are mean ± SD of 
triplicate samples from one representative experiment of four performed. *p < 0.05; **p < 0.01 (Student’s t-test).
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(i) direct cell-to-cell contact-mediated recognition of allogeneic 
MHC class II specificities and (ii) physiological-like stimulation 
conditions. CD6 is a complex molecule as its entire function rests 
on integrating CD6–CD166/ALCAM cell adhesion phenomena 
and the modulatory signals triggered by its cytoplasmic domain. 
Our MLR and cGvHD-induced lupus-like disease models allow 
for simultaneous evaluation of these two aspects of CD6 biol-
ogy in  vitro and in  vivo. We observe low in  vitro and in  vivo  
T (and B) lymphoproliferative responses to allogeneic stimulation 
in CD6−/− mice, which in turn exhibit exacerbated autoimmune 
events (namely, high titers of anti-dsDNA and anti-nucleosome 
autoantibodies characteristic of lupus-like disorders). These 
apparently opposing effects likely reflect the complex nature of 
CD6 function.
In vitro MLR assays reveal induction of (i) lower lymphopro-
liferative responses and (ii) higher generation of CD25+FoxP3+ 
cells with low LAP expression, in CD6−/− T  cells. These two 
findings are not reproducible via direct TCR/CD3 cross-linking 
and/or presence of costimulatory agents. The first one is in agree-
ment with a critical role for CD6–CD166/ALCAM interaction 
in optimal IS formation and subsequent T-cell activation and 
proliferation (14–16). Unaffected proliferative responses of 
CD6−/− T  cells to direct TCR/CD3 cross-linking argue against 
cell-intrinsic T-cell defects and suggests suboptimal cell contact-
dependent T–APC interactions in MLR-induced T-cell prolifera-
tion. The second finding indicates that low lympho-proliferation 
does not respond only to unsteady T–APC contacts but also 
to a simultaneous decrease in IL-2 availability associated with 
induced CD25+FoxP3+ cells with low activated (LAP) phenotype. 
Thus, absence of CD6-CD166/ALCAM interactions disrupts the 
equilibrium required in adaptive immune responses. This find-
ing was masked by the use of standard stimulation conditions 
for in vitro Treg generation (plate-bound anti-CD3 plus anti-CD28 
mAbs and inducing cytokines), which further calls for the need of 
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experimental systems that resemble, in as much as possible, real 
physiological settings (40).
The need for TCR/CD3-mediated signaling in homeostasis 
and Treg suppressing action is well established (6). Also, low or 
interrupted TCR/CD3 stimulation favors FoxP3 expression both 
in vivo and in vitro (41, 42). Then, suboptimal T–APC contacts 
under CD6 deficiency may account for CD25+FoxP3+ cell induc-
tion. Moreover, ablation of the key TCR signal transducing effec-
tors SLP-76 and PLC-γ1(43) are critical for Treg function. Indeed, 
CD6 interacts directly with SLP-76 upon TCR engagement and 
phosphorylation by Zap70 (21, 25). Thus, altered TCR signaling 
due to inefficient recruitment of SLP-76 in CD6−/− T cells may 
also be behind altered Treg induction and/or function. Finally, the 
modulatory effects of CD6 signaling on TCR-mediated activation 
should be accounted for in this regard. Recent evidence points to 
a negative modulatory role for CD6, rather than a costimulatory 
one, in TCR signaling (20, 29). Even though CD6−/− and CD6+/+ 
C57BL/6 mice during CD3 cross-linking-induced proliferative 
responses and mRNA expression, a CD6-mediated negative 
modulation of TCR signaling cannot be fully excluded. Indeed 
recent data from CD6−/− DBA/1 mice show upregulated expres-
sion of early T-cell activation markers CD25 and CD69 together 
with reduced T-cell survival and proliferation following CD3 
and CD28 co-cross-linking (44). Whether genetic differences 
between mouse strains are behind these apparent discrepancies 
would deserve further exploration.
The in  vivo relevance of the MLR observations was con-
firmed in mice undergoing cGvHD-induced lupus-like disease. 
Splenomegaly at the end of the experimental period (week 5)—a 
hallmark of the cGvHD-induced autoimmunity model—was 
lower in CD6−/− mice and explained by lower in vivo proliferation 
(low BrdU incorporation in the absence of vis-à-vis differences 
in apoptotic cell levels). Reduced in vivo proliferation was at the 
expense of the B-cell compartment and associated with higher 
frequency of follicular (B2) B cells. Importantly, in vitro prolifera-
tive responses of CD6−/− B cells to direct cross-linking of the B-cell 
receptor complex were unaffected, excluding B  cell-intrinsic 
defects. The reduced in vivo proliferation of CD6−/− B cells may 
then respond to suboptimal cooperative T–B cell responses since 
(i) CD6 and CD166/ALCAM are constitutively expressed on 
T and B  cells, respectively, and (ii) the CD6–CD166/ALCAM 
interaction is critical for optimal IS formation and stabilization.
Reduced B-cell proliferative responses do not prevent CD6−/− 
mice from exacerbated autoantibody production after cGvHD 
induction (or spontaneously in aged animals) and correlate 
with the basal and inducible levels of Treg cells with low LAP 
expression/suppressive function. Untreated CD6−/−mice show 
high levels of CD4+CD25+FoxP3+ T cells and low T- and B-cell 
proliferation suppression induced via CD3- (29) or IgM-cross-
linking, together with increased autoantibody production in the 
absence of changes in stimulatory TFH and inhibitory TFR cell 
frequency. It is known that in response to T-dependent antigens 
a proportion of naïve Treg express the follicular homing receptor 
CXCR5 (45) and that the resulting TFR control the numbers and 
function of TFH, inhibiting non-antigen-specific B cells, includ-
ing those carrying self-reactive receptors (45). Taken together, 
these observations suggest that dysfunctional Treg cells migrating 
to B-cell areas may account for the hyperreactive autoantibody 
phenotype seen in CD6−/− mice.
Following cGvHD-induced lupus-like disease, CD6−/− mice 
showed higher induction of CD4+CD25+FoxP3+ cells with lower 
surface levels of the Treg activation marker LAP, in line with their 
MLR-induced counterparts. Again, these cells from CD6−/− mice 
were less efficient in suppressing the MLR-induced proliferation. 
No differences were observed in relative mRNA expression after 
direct TCR/CD3 cross-linking, which together with the absence 
of CD25+FoxP3+ cell and LAP surface expression during standard 
in vitro Treg induction (anti-CD3 plus anti-CD28 in the presence 
of TGF-β and IL-2) argue against intrinsic defects in CD6−/− Treg 
cells. Thus, the reduced suppression observed in ex vivo isolated 
CD6−/− cells with Treg phenotype (both basally and post cGvHD 
induction) could account for defective cell contact-dependent 
events.
In summary, our results suggest first a direct involvement of 
CD6–CD166/ALCAM interaction in peripheral T-cell responses 
induced by cell contact-dependent antigen presentation; second, 
a role for CD6 in the maintenance of tolerance; and third, an 
incipient model for the molecular basis underlying CD6 targeting 
therapies, the latter in line with CD6 susceptibility gene variants 
for multiple sclerosis (5, 6), Behçet’s disease (46), and CD6 
deranged expression in Sjögren’s syndrome patients (47).
Recent approaches to CD6 targeting therapies include itoli-
zumab, a humanized anti-CD6 mAb in psoriasic patients (2, 48), 
in view to extend its use to rheumatoid arthritis (49) and Sjögren’s 
syndrome (50). The latter is based on the in vitro inhibition by 
itolizumab of T-cell activation and differentiation to Th1 effector 
cells (51). However, mAb-induced CD6 cross-linking may also 
block CD6–CD166/ALCAM interaction by steric hindrance 
(52) or internalization (4), mimicking a “CD6-deficient like” 
phenotype. In this case, itolizumab would affect cell proliferative 
responses, in a similar way to what we observe in CD6−/− mice.
Contrary to the situation in mice, human Treg cells present low/
negative CD6 expression (53), rendering itolizumab ineffective on 
this T-cell subset. Interestingly, the successful use of mAb-induced 
depletion of CD6+ T cells in prevention of GvHD in bone marrow 
transplants could be explained by the preservation of human Treg 
cell subset in such a therapeutic setting (54). Moreover, the result-
ing CD6− T cell population showed reduced alloreactivity in MLR 
assays (55) coincidental with our CD6−/− data.
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